| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Niagen Bioscience, Inc.$3.24
+0.01 (+0.31%)
Market Cap
291.50 M
EPS
0.23
P/E Ratio
16.77 $
Value Trade
2.19 M
SEC Financials
Q1 2026Dilution Risk
Revenue
31.47 M
R&D Expenses
1.48 M
Operating CF
-1.19 M
Total Assets
114.33 M
Total Liabilities
32.00 M
Equity
82.33 M
D/E Ratio
12,345
-2.14 %
Week
-23.91 %
1 Month
-25.46 %
3 Month
-45.62 %
6 Month
-53.96 %
5 Year
-88.38 %
All Time
Cash Data
Cash Position
66.55 M
Monthly Burn
398.00 K
Runway
164.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
64.75 K
52 Week Range
3.57 - 14.69
% held by Insiders
34.11 %
% held by Institutions
46.63 %
Enterprise Value
227.53 M
Total Shares
79.69 M
Short %
9.23 %
Float Shares
51.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Niagen Bioscience, Inc.
260Total events
1Upcoming
60Tier-1 (high impact)
2012 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
▲Rare Pediatric DiseaseNB4168Designation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NIAGEN PriorityOrphan | — | — | 2015-02-11 | a single dose of NR resulted in statistically significant increases in the co-enzyme nicotinamide adenine dinucleotide (NAD+) Read More | ChromaDex's NIAGEN Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study - Results Confirm That NR Increases the Mitochondrial Co-enzyme NAD+ and is Safe - - Full Study Results to be Peer Reviewed fo Read More | |
NIAGEN PriorityOrphan | — | — | 2015-02-11 | a single dose of NR resulted in statistically significant increases in the co-enzyme nicotinamide adenine dinucleotide (NAD+) Read More | ChromaDex's NIAGEN Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study - Results Confirm That NR Increases the Mitochondrial Co-enzyme NAD+ and is Safe - - Full Study Results to be Peer Reviewed fo Read More | |
NIAGEN PriorityOrphan | — | — | 2015-02-11 | a single dose of NR resulted in statistically significant increases in the co-enzyme nicotinamide adenine dinucleotide (NAD+) Read More | ChromaDex's NIAGEN Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study - Results Confirm That NR Increases the Mitochondrial Co-enzyme NAD+ and is Safe - - Full Study Results to be Peer Reviewed fo Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NAGE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NAGE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NAGE▲ +0.3%today
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
Niagen Bioscience, Inc. will be represented at Canaccord Genuity's 46th Annual Growth Conference. CEO Rob Fried and CFO Ozan Pamir will participate, with Fried scheduled for a fireside chat on August 11, 2026. This event emphasizes the company's commitment to healthy aging and NAD+ research.
Read more →NAGENiagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Niagen Bioscience, Inc. will report its second quarter 2026 financial results on August 4, 2026. A conference call is scheduled for 4:30 p.m. ET to discuss these results. The announcement reflects the company's commitment to transparency and communication with stakeholders.
Read more →NAGENiagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research, effective July 20, 2026. In this role, Dr. Kale will lead the Global Niagen Research Program, managing the company's academic and clinical research collaborations. This strategic move aims to enhance the company's focus on healthy aging.
Read more →NAGENiagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Niagen Bioscience has received Rare Pediatric Disease Designation from the FDA for its drug candidate NB4168, aimed at treating Ataxia Telangiectasia (A-T). This designation may facilitate faster development and approval processes. Additionally, the European Medicines Agency has granted Orphan Medicinal Product Designation for the same treatment, highlighting its potential significance in pediatric care.
Read more →NAGENiagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience's CEO, Rob Fried, is set to participate in a virtual fireside chat on July 15, 2026, hosted by KCSA Strategic Communications. The discussion will focus on the company's newly launched pharmaceutical program targeting rare genetic diseases and aging-related disorders. This event aims to enhance awareness of Niagen's initiatives in the biopharma sector.
Read more →NAGENiagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
Niagen Bioscience has launched its first drug candidate through NAD Pharmaceuticals Corp., targeting accelerated aging and rare genetic diseases. This initiative emphasizes the role of NAD+, a vital coenzyme involved in energy metabolism and cellular functions. The program aims to develop therapies that leverage NAD+ for treating these conditions.
Read more →NAGENiagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience is scheduled to present at the 16th Annual East Coast IDEAS Investor Conference. The event will provide an opportunity for the company to engage with investors and discuss its latest developments. Further details about the presentation or the company's agenda were not disclosed.
Read more →NAGENiagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience has renamed its External Research Program to the Niagen Research Program. This change aims to reinforce its leadership position in NAD+ science. The rebranding reflects the company's commitment to advancing research in this area, although specific details about new initiatives were not provided.
Read more →NAGENiagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience has announced its participation in upcoming investor conferences. This move is expected to enhance the company's visibility among investors. Further details regarding the specific conferences and the agenda have not been disclosed in the announcement.
Read more →NAGENiagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience, Inc. has reported its financial results for the first quarter of 2026. The article provides insights into the company's performance, but lacks detailed information regarding specific financial metrics or future outlook.
Read more →NAGEDocument Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjust
Niagen Bioscience, Inc. reported its financial results for the first quarter of 2026, with net sales rising to $31.5 million, a 3% increase year-over-year. The company also achieved a gross margin of 63.5% and net income of $6.3 million, up from the previous year's $5.1 million. Notable operational highlights include the launch of a telehealth platform and diversification of products and channels. However, the company faced a cash outflow of $1.2 million due to increased inventory and higher operational costs.
Read more →NAGENiagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience has launched the Niagen Plus Telehealth Platform, which includes an innovative at-home injection kit. This new offering aims to improve patient accessibility and convenience in receiving treatments. The platform is designed to provide a seamless telehealth experience for users.
Read more →NAGENiagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience has partnered with Olympia Pharmaceuticals to enhance its distribution of Niagen Plus™ products. Olympia, an FDA-registered 503B outsourcing facility, will compound and distribute pharmaceutical-grade Niagen® (nicotinamide riboside). This collaboration aims to support the company's focus on healthy aging.
Read more →NAGE▲ +5.9%on this news
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience, Inc. will report its first quarter 2026 financial results on May 6, 2026, during a conference call at 4:30 p.m. ET. The results will be available in a press release after market hours. The company is recognized for its leadership in NAD+ science and aims to enhance healthy aging.
Read more →NAGENiagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
Niagen Bioscience, Inc. has announced the publication of a United States Pharmacopeia (USP) dietary supplement ingredient monograph for Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in its flagship product, Niagen®. This milestone underscores the scientific credibility of Niagen and the company's commitment to healthy aging.
Read more →NAGENiagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience has partnered with OneSpaWorld to offer Niagen IV at over 80 Medi-Spa clinics on cruise ships. This collaboration marks Niagen's first venture into cruise ship clinics, enhancing access to their NAD-boosting treatments for travelers. The new Niagen IV formulation promises a better patient experience with shorter infusion times and higher NAD+ blood levels.
Read more →NAGENiagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience has announced an increase in its share repurchase program from $10 million to $20 million, reflecting the Board of Directors' confidence in the company's strategy and long-term value proposition. Since the initiation of the program, approximately $2.6 million of common stock has already been repurchased. The program is authorized to continue until October 31, 2027, allowing management flexibility in executing buybacks as deemed beneficial.
Read more →NAGENiagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience has surpassed 300 material transfer agreements with global research institutions, marking a significant milestone in NAD+ research. This program has led to 45 published clinical studies, reinforcing Niagen's position as a leading NAD+ booster. The company anticipates further expansion into new research areas and institutions as interest in NAD+ biology grows.
Read more →NAGENiagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Niagen Bioscience reported a strong financial performance for the fiscal year 2025, with net sales increasing by 30% to $129.4 million and net income rising by 103% to $17.4 million. The company also achieved a gross margin improvement of 250 basis points. Despite a rise in operating expenses, the outlook for 2026 remains positive, projecting 10-15% growth.
Read more →NAGENiagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Niagen Bioscience has announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction, effective February 24, 2026. This move aims to streamline operations and concentrate on NAD+ science and commercial growth. CEO Rob Fried emphasized the importance of focusing resources on high-impact opportunities for shareholders.
Read more →NAGENiagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction Divestiture streamlines operations and advances the Company's strategy to fu
Niagen Bioscience has announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction. This divestiture is part of the company's strategy to streamline operations and focus on its core expertise in NAD+ science and healthy aging. By exiting non-core activities, Niagen aims to allocate resources more effectively towards growth opportunities in the longevity industry. The CEO noted that this strategic move is designed to enhance capital and talent allocation for maximum shareholder impact.
Read more →NAGENiagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
Niagen Bioscience, Inc. has announced its role as the premiere sponsor of the inaugural 'NAD for Health: Opportunities & Challenges' conference at the University of Copenhagen, scheduled for March 23-25, 2026. The conference will focus on NAD metabolism and its implications for health, featuring discussions among researchers and clinicians. The event aims to address barriers in NAD research and promote collaboration across disciplines.
Read more →NAGENiagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
Niagen Bioscience, Inc. will hold a conference call on March 4, 2026, to discuss its financial results for Q4 and fiscal year 2025. The results will be released after market close on the same day. The call will provide insights into the company's performance and future outlook.
Read more →NAGENiagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
Niagen Bioscience has partnered with Truemed to allow customers to purchase Tru Niagen using HSA and FSA funds. This initiative aims to enhance accessibility for consumers seeking the leading NAD+ supplement in the U.S. The partnership simplifies the purchasing process and is supported by significant scientific research backing the product's efficacy.
Read more →NAGENiagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Niagen Bioscience has acquired a comprehensive patent portfolio for nicotinamide riboside (NR) from Queen’s University Belfast, solidifying its leadership in NAD+ precursor intellectual property. This acquisition grants Niagen sole ownership of critical patents covering NR production and composition, enhancing its strategic and operational capabilities. The company aims to leverage this portfolio for future pharmaceutical applications.
Read more →NAGENiagen Bioscience Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intell
Niagen Bioscience has acquired a comprehensive portfolio of patents covering nicotinamide riboside (NR) from Queen's University Belfast, solidifying its position in the NAD+ industry. This acquisition provides Niagen with complete ownership of essential intellectual property related to NR, bolstering its defenses against potential infringers. The patents cover various aspects of NR, including production and commercial use, thus enhancing the company’s strategic capabilities. This move is expected to drive future advancements in healthspan and pharmaceutical applications.
Read more →NAGENiagen Bioscience Announces $10 Million Share Repurchase Program
Niagen Bioscience, Inc. has announced a $10 million share repurchase program, which is set to be executed over the next 24 months. The Board of Directors approved this initiative as a strategic use of the company's capital. CEO Rob Fried expressed confidence in the program as a means to enhance shareholder value. The repurchase may be conducted through various methods, depending on market conditions, although the company is not obligated to repurchase any shares.
Read more →NAGEDocument Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6
Niagen Bioscience, Inc. reported a strong performance for Q3 2025, with net sales increasing by 33% to $34.0 million, driven primarily by the success of its Tru Niagen product. The company also experienced a notable improvement in gross margins, reflecting enhanced operational efficiency. Adjusted EBITDA more than doubled, showcasing significant profitability growth. Looking ahead, Niagen reaffirmed its full-year sales forecast, indicating continued momentum for its products and marking a positive outlook for the future.
Read more →NAGEDocument Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6
Niagen Bioscience, Inc. reported strong second quarter financial results for 2025, with net sales rising by 37% to $31.1 million and net income of $3.6 million compared to breakeven in the prior year. The company raised its full-year revenue outlook to 22% to 27% growth, supported by significant gains in both product segments. Meanwhile, adjusted EBITDA increased by 221% to $5.0 million. However, concerns were noted regarding the potential sustainability of gross margin improvements and rising operating expenses.
Read more →NAGEDocument Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 milli
Niagen Bioscience, Inc. reported strong financial results for the first quarter of 2025, with total net sales of $30.5 million, reflecting a 38% year-over-year increase. A notable gross margin of 63.4% and net income of $5.1 million demonstrated improved profitability compared to the previous year. The company also revised its full-year 2025 outlook to expect revenue growth between 20% to 25%, supported by both Tru Niagen and the demand for Niagen ingredients. However, general and administrative expenses are anticipated to rise significantly due to various investments, indicating potential challenges ahead.
Read more →NAGEChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science The rebrand celebrates the company's clinically proven flagship patented nicotinamide riboside (NR) i
Niagen Bioscience, formerly known as ChromaDex Corp., has undergone a strategic rebrand to emphasize its focus on NAD+ research and healthy aging solutions. The company's flagship product, Niagen, is recognized as a high-quality, clinically proven nicotinamide riboside (NR) supplement. With a legacy of over 25 years, Niagen Bioscience aims to expand its scientific discoveries and potential partnerships in the bioscience and healthcare sectors. The company also reported strong financial results, indicating a positive trajectory for its NAD+ boosting products.
Read more →NAGEChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 milli
ChromaDex Corporation reported strong financial results for the fourth quarter and fiscal year 2024, with net sales increasing 19% year-over-year to $99.6 million and a net income of $8.6 million, a recovery from the previous year's losses. The company also improved its gross margin to 61.8% and reported positive operating cash flows of $12.1 million. The launch of the Niagen Plus product line and receipt of regulatory designations from the FDA for its new Indications further underline its growth trajectory. For fiscal year 2025, ChromaDex projects continued revenue growth of approximately 18%, driven by e-commerce expansion and increased market presence.
Read more →NAGEDocument ChromaDex Corporation Reports Third Quarter 2024 Financial Results Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and Adjusted EBITDA of $1.9
ChromaDex Corporation reported strong financial results for the third quarter of 2024, with net sales reaching $25.6 million, a 31% increase year-over-year. The gross margin improved to 63.5%, while the company achieved record net income of $1.9 million and adjusted EBITDA of $2.9 million. Additionally, ChromaDex expanded the availability of its Niagen+ product line to over 100 wellness clinics. Despite increased operating expenses and legal costs, the outlook for continued revenue growth remains optimistic, driven by the success of new product launches and e-commerce ventures.
Read more →NAGEDocument ChromaDex Corporation Reports Second Quarter 2024 Financial Results Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven
ChromaDex Corporation announced its financial results for Q2 2024, reporting total net sales of $22.7 million, a 12% increase compared to the previous year. The gross margin was solid at 60.2%, and the company achieved positive adjusted EBITDA of $1.6 million. Despite these improvements, ChromaDex experienced a net loss at breakeven and a notable decrease in cash inflow from operations. The launch of the new Niagen+ product line is expected to strengthen the company's market position and support future revenue growth.
Read more →NAGEDocument ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three
ChromaDex Corporation reported its first-quarter financial results for 2024, showcasing net sales of $22.2 million and a gross margin of 60.7%. Despite a net loss of $0.5 million, the company's Adjusted EBITDA improved to a positive $0.7 million. ChromaDex reiterated its full year outlook with expectations for at least 16% net sales growth, supported by new distribution partnerships and increased investments in research and development. However, the company experienced a 2% decline in net sales compared to the previous year, primarily due to reduced sales through distributor partners.
Read more →NAGEChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% fro
ChromaDex Corporation has reported its financial results for the fourth quarter and full year 2023, showing positive growth in net sales and gross margins. The company achieved net sales of $21.2 million in the fourth quarter, with a gross margin of 61.0%. Although it posted a net loss of $4.9 million for the year, this was a significant improvement from the previous year's losses. ChromaDex also highlighted successful product launches and partnerships aimed at enhancing its market reach and revenue growth moving forward.
Read more →NAGEDocument ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 mill
ChromaDex Corporation reported its third quarter 2023 financial results, posting total net sales of $19.5 million and a gross margin of 61.4%. The company achieved a positive Adjusted EBITDA of $0.5 million, despite a net loss of $1.0 million. Sales of the flagship product, Tru Niagen, increased significantly, contributing to a year-over-year revenue growth of 14%. Looking ahead, ChromaDex aims for continued growth in 2023 driven by its e-commerce initiatives and new partnerships.
Read more →NAGEDocument ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjuste
ChromaDex Corporation reported strong financial results for the second quarter of 2023, featuring total net sales of $20.3 million and a gross margin of 60.8%. The company achieved a positive Adjusted EBITDA of $0.2 million and improved its net loss to $2.2 million compared to the previous year. Furthermore, ChromaDex noted a significant reduction in operating expenses and is raising its 2023 revenue outlook to at least a 15% growth, reflecting positive market trends and operational improvements. The company continues to invest in research and development to further enhance its product offerings.
Read more →NAGEDocument ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of onl
ChromaDex Corporation reported financial results for the first quarter of 2023, highlighting record net sales of $22.6 million, marking a 31% increase from the previous year. The company showed a strong gross margin of 59.9% and managed to reduce operating expenses significantly. Despite a net loss of $1.9 million, this was an improvement compared to the prior year. The company is optimistic about future growth, raising its revenue outlook by expecting at least 12.5% growth for the full year 2023.
Read more →NAGEChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EB
ChromaDex Corporation reported strong financial results for Q4 and the full year of 2022, achieving record revenues of $21.0 million, an 18% increase compared to Q4 2021. Adjusted EBITDA improved to a profit of $0.4 million, reflecting operational progress, though the company still faced a net loss of $1.4 million for the quarter. Notably, the company secured a long-term agreement with Nestlé Health Science and made strides in securing new patents, positioning itself for future growth despite ongoing economic challenges.
Read more →NAGEDocument ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 mil
ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 million and $1.2 million, respectively, for the three months ended Sept
Read more →NAGEDocument ChromaDex Corporation Reports First Quarter 2022 Financial Results Total net sales of $17.3 million for the three months ended
ChromaDex Corporation Reports First Quarter 2022 Financial Results Total net sales of $17.3 million for the three months ended March 31, 2022, up 18% from the prior year, with $14.9 million from Tru Niagen and gross margin of 61.0% for the quarter. LOS ANGELES, CA - May 12, 202
Read more →NAGEDocument ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen and gross margin of 61
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended Dec
Read more →NAGEDocument ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17.3 million for the three months ended
ChromaDex Corporation Reports Third Quarter 2021 Financial Results Total company net sales of $17.3 million for the three months ended September 30, 2021, with Tru Niagen net sales of $14.8 million, up 24% from the prior year quarter and gross margin of 61.1% for the quarter. L
Read more →NAGEDocument ChromaDex Corporation Reports Second Quarter 2021 Financial Results Tru Niagen net sales of $15.4 million for the three months ended
ChromaDex Corporation Reports Second Quarter 2021 Financial Results Tru Niagen net sales of $15.4 million for the three months ended June 30, 2021, up 31% from the prior year quarter, with total company net sales of $17.7 million and gross margin of 61.1% for the quarter. LOS A
Read more →NAGEChromaDex Corporation Reports First Quarter 2021 Financial Results Tru Niagen® Revenue for the Three-Month Period Ended
ChromaDex Corporation Reports First Quarter 2021 Financial Tru Niagen Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of LOS ANGELES, May 6, 2021 (GLOBE NEWSWIRE)
Read more →NAGEChromaDex Corporation Reports 2020 Financial Results Revenue for the Three-Month Period Ended
ChromaDex Corporation Reports 2020 Financial Results Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses. Full Year Revenue of $59.3 Million, with $47.1 Million from T
Read more →NAGESECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ” ) is dated as of
SECURITIES PURCHASE AGREEMENT Securities Purchase Agreement (this Agreement ) is dated as of February 20, 2021, between ChromaDex Corporation, a Delaware corporation (the Company ), and the purchaser identified on the signature pages hereto (including its successors and assi
Read more →NAGEChromaDex Corporation Reports Third Quarter 2020 Financial Results Revenue for the Three-Month Period Ended
ChromaDex Corporation Reports Third Quarter 2020 Financial Revenue for the Three-Month Period Ended September 30, 2020 Totals $14.2 Million, up 18% Year-over-Year, with Gross Margin of 59.6%, and Lower Operating Expenses LOS ANGELES, November 4, 2020 (BUSINESS WIRE) - ChromaD
Read more →NAGECHROMADEX CORPORATION REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Second Quarter 2020 Highlights vs. Second Quarter 2019 ● Strong growth in net sales to $15.3 million, higher gross margins, and significantly imp
CHROMADEX CORPORATION REPORTS SECOND QUARTER 2020 FINANCIAL Second Quarter 2020 Highlights vs. Second Quarter 2019 Strong growth in net sales to $15.3 million, higher gross margins, and significantly improved marketing efficiency Tru Niagen net sales of $11.7 million, a 34% i
Read more →NAGEChromaDex Corporation AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors
ChromaDex Corporation AMENDED 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockh
Read more →NAGECHROMADEX CORPORATION REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS First Quarter 2020 Highlights vs. First Quarter 2019 ● Strong growth in net sales to $14.3 million, higher gross margins, and significantly improv
CHROMADEX CORPORATION REPORTS FIRST QUARTER 2020 FINANCIAL First Quarter 2020 Highlights vs. First Quarter 2019 Strong growth in net sales to $14.3 million, higher gross margins, and significantly improved marketing efficiency Tru Niagen net sales of $11.1 million, a 50% incr
Read more →NAGECHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 ● Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018 Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency TRU NIAGEN net sales of $10.2 million, a 57% increase
Read more →NAGECHROMADEX CORPORATION REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Third Quarter 2019 Highlights vs. Third Quarter 2018 ● Strong growth in net sales to $12.1 million, improved gross margin, and significantly impro
CHROMADEX CORPORATION REPORTS THIRD QUARTER 2019 FINANCIAL Third Quarter 2019 Highlights vs. Third Quarter 2018 Strong growth in net sales to $12.1 million, improved gross margin, and significantly improved marketing efficiency TRU NIAGEN net sales of $9.7 million, an 11% inc
Read more →NAGECONFIDENTIAL EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “ Agreement ” ) is made as of
REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (the Agreement ) is made as of August 15, 2019 by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the Company ), and the several purchasers signatory he
Read more →NAGECONFIDENTIAL EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ” ) is dated as of
SECURITIES PURCHASE AGREEMENT Securities Purchase Agreement (this Agreement ) is dated as of August 13, 2019, between ChromaDex Corporation, a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its successors and
Read more →NAGECHROMADEX CORPORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS - Second Quarter 2019 Net Revenues Increased by 42% to $11.1 Million - Second Quarter 2019 Highlights vs. Second Quarter 2018 ● Strong growth in
CHROMADEX CORPORATION REPORTS SECOND QUARTER 2019 FINANCIAL - Second Quarter 2019 Net Revenues Increased by 42% to $11.1 Second Quarter 2019 Highlights vs. Second Quarter 2018 Strong growth in net sales to $11.1 million, significantly higher gross margins, and improved market
Read more →NAGEOMNIBUS AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTES This Omnibus Amendment to Note Purchase Agreement and Convertible Promissory Notes (this “ Amendment ”), dated as of
OMNIBUS AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY Omnibus Amendment to Note Purchase Agreement and Convertible Promissory Notes (this dated as of June 30, 2019 (the Effective Date ), by and among ChromaDex Corporation, a Delaware corporation (the the n
Read more →NAGEChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN® ChromaDex Corporation and Nestlé Health Science agreement includes global commercial license a
ChromaDex Corp. and Nestl Health Science Enter Global Commercial License and Supply Agreement for TRU ChromaDex Corporation and Nestl Health Science agreement includes global commercial license and supply agreement for ingredient sales of TRU NIAGEN for certain products with
Read more →NAGEEXECUTION VERSION NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “ Agreement ” ) is dated as of
NOTE PURCHASE AGREEMENT Note Purchase Agreement (this Agreement ) is dated as of May 9, 2019, between ChromaDex Corporation, a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a Purc
Read more →NAGECHROMADEX CORPORATION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS - First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 ● Strong start to the y
CHROMADEX CORPORATION REPORTS FIRST QUARTER 2019 FINANCIAL - First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased mar
Read more →NAGECHROMADEX CORPORATION REPORTS 2018 FINANCIAL RESULTS - Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights
CHROMADEX CORPORATION REPORTS 2018 FINANCIAL RESULTS - Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and
Read more →NAGEPRESENTATION Untitled Document
PRESENTATION Untitled Document
Read more →NAGECHROMADEX CORPORATION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS -Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million - Third Quarter 2018 Highlights vs. Third Quarter 2017 ● Net sales up 33%, fuele
CHROMADEX CORPORATION REPORTS THIRD QUARTER 2018 FINANCIAL -Third Quarter 2018 Net Revenues Increased by 33% to $8.1 Million Third Quarter 2018 Highlights vs. Third Quarter 2017 fueled by growth of TRU NIAGEN , which increased by TRU NIAGEN sales at 84% of NIAGEN-related sale
Read more →NAGEChromaDex and Dartmouth College File Patent Infringement Lawsuit Against Elysium Health
ChromaDex and Dartmouth College File Patent Infringement Lawsuit Against Elysium Health IRVINE, Calif., Sept. 18, 2018 ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGE
Read more →NAGEE xhibit 99.1 CHROMADEX CORPORATION REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS -Second Quarter 2018 Net Revenues Increased by 85% to $7.8 Million
CHROMADEX CORPORATION REPORTS SECOND QUARTER 2018 FINANCIAL -Second Quarter 2018 Net Revenues Increased by 85% to $7.8 Million IRVINE, Calif., August 9, 2018 (GLOBE NEWSWIRE) - ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improv
Read more →NAGEChromaDex Corporation 2017 Equity Incentive Plan Adopted by the Board of Directors
ChromaDex Corporation 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders:
Read more →NAGECHROMADEX CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS -First Quarter 2018 Net Revenues Increased by 95% to $6.6 Million
CHROMADEX CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL -First Quarter 2018 Net Revenues Increased by 95% to $6.6 Million IRVINE, Calif., May 10, 2018 (GLOBE NEWSWIRE) - ChromaDex Corporation (NASDAQ: CDXC), science-based, integrated nutraceutical company devoted to improv
Read more →NAGEChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director New Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated
Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated Nutraceutical IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) ChromaDex Corp.
Read more →NAGECHROMADEX CORPORATION REPORTS 2017 FINANCIAL RESULTS -Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million
CHROMADEX CORPORATION REPORTS 2017 FINANCIAL RESULTS -Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million IRVINE, Calif., March 8, 2018 (GLOBE NEWSWIRE) - ChromaDex Corporation (NASDAQ: CDXC), science-based, integrated nutraceutical company devoted to improving
Read more →NAGECHROMADEX CORPORATION REPORTS PRELIMINARY 2017 RESULTS - Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million - Irvine, CA –
CORPORATION REPORTS PRELIMINARY 2017 RESULTS Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million - Irvine, CA February 12, 2018 - ChromaDex Corporation (NASDAQ: CDXC), a science-based, integrated nutraceutical company devoted to pioneering tec
Read more →NAGEChromaDex Reports Third Quarter 2017 Financial Results -Company Reports Third Quarter 2017 Revenue of $6.1 Million, Up 55% Compared to Last Year - - Continued Progress on Building a Consumer Products Platform Around TRU
Reports Third Quarter 2017 Financial Results -Company Reports Third Quarter 2017 Revenue of $6.1 Million, Up 55% Compared to Last Year - - Continued Progress on Building a Consumer Products Platform IRVINE, Calif., Nov. 9, 2017 ChromaDex Corp. (NASDAQ: CDXC), a science-based
Read more →NAGEChromaDex Appoints Kevin Farr as New
ChromaDex Appoints Kevin Farr as New IRVINE, Calif., Oct. 9, 2017 ChromaDex Corp. (NASDAQ: CDXC), an innovator of science-based, proprietary health and wellness consumer products and ingredient technologies that promote health longevity, announced today that it has appointed
Read more →NAGEChromaDex Sells its Analytical Testing Business to LabCorp, to Accelerate the Expansion of Nicotinamide Riboside and its Other Patented Ingredient Technologies
ChromaDex Sells its Analytical Testing Business to LabCorp, to Accelerate the Expansion of Nicotinamide Riboside and its Other Patented Ingredient Technologies IRVINE, Calif., August 23, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary hea
Read more →NAGEChromaDex Announces Closing of Third and Final Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing and Appoints Two Additional Board Members -Company Appoints Wendy Yu and Tony Lau to Board of Director
ChromaDex Announces Closing of Third and Final Tranche of $25 Million Strategic Investment Led by Mr. Li Ka-shing Appoints Two Additional Board Members -Company Appoints Wendy Yu and Tony Lau to Board of IRVINE, Calif., Aug. 21, 2017 ChromaDex Corp. (NASDAQ: CDXC), an innov
Read more →NAGEChromaDex Reports Second Quarter 2017 Financial Results -Company Reports Revenue of $5.3 Million for Q2 2017- - Continued Progress on Building a Consumer Products Platform Around TruNiagen®
ChromaDex Reports Second Quarter 2017 Financial -Company Reports Revenue of $5.3 Million for Q2 2017- - Continued Progress on Building a Consumer Products Platform IRVINE, Calif., August 10, 2017 ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness an
Read more →NAGEChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN ® in treating breast cancer
ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN in treating IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprie
Read more →NAGEFIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT THIS FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “ Amendment ”), dated as of
SECURITIES PURCHASE AGREEMENT FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this Amendment ), dated as of May 24, 2017, is entered into by and among ChromaDex Corporation, a Delaware corporation (the Company ), Champion River Ventures Limited ( Champion River ) and Pion
Read more →NAGEChromaDex Reports First Quarter 2017 Financial Results - Changes in Q1 and new investor set the foundation for success with NIAGEN ®
ChromaDex Reports First Quarter 2017 Financial Results - Changes in Q1 and new investor set the foundation for success IRVINE, Calif., May 11, 2017 ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-
Read more →NAGEREGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “ Agreement ”) is made as of
REGISTRATION RIGHTS AGREEMENT (the Agreement ) is made as of April 29, 2017 by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the several purchasers signatory hereto (each, a Purchaser and collectively, the Purch
Read more →NAGESECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of
Securities Purchase Agreement (this Agreement ) is dated as of April 26, 2017, between ChromaDex Corporation, a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a Purchaser and colle
Read more →NAGEChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of IRVINE, Calif., March 28, 2017 ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, s
Read more →NAGEChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34% -Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22%
ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew -Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased IRVINE, Calif., March 16, 2017 ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creat
Read more →NAGEA Letter from the ChromaDex Chief Executive Officer
A Letter from the ChromaDex Chief Executive Officer Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) - The following is issued on behalf of ChromaDex: Fellow Shareholders: January 2016, I issued a shareholder letter wherein I described in some detail my enthusiasm surrounding the eno
Read more →NAGEChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29% - Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million –
ChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29% - Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million IRVINE, Calif., February 14, 2017 ChromaDex Corp. (NASDAQ: CDXC)
Read more →NAGEChromaDex Reports Third Quarter 2016 Financial Results -Company Reports Revenue of $21.2 million for first 9 months 2016 and is on track for another record revenue year -Company Reports Revenue of $5.0 million for Q3 201
ChromaDex Reports Third Quarter 2016 Financial Reports Revenue of $21.2 million for first 9 months 2016 and is on track for another record revenue year -Company Reports Revenue of $5.0 million for Q3 -Accelerating trend of peer-reviewed research validating NR continued durin
Read more →NAGEChromaDex Establishes $5 Million Credit Facility with Bridge Bank
ChromaDex Establishes $5 Million Credit Facility with Bridge IRVINE, Calif., November 8, 2016 ChromaDex Corp. innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports
Read more →NAGEChromaDex Appoints Kurt Gustafson to its Board of Directors
ChromaDex Appoints Kurt Gustafson to its Board of IRVINE, Calif., Oct. 27, 2016 ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care,
Read more →NAGE1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- -39- -40- -41- -42
1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- -39- -40- -41- -42-
Read more →NAGEChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period -Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000
ChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period -Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000- IRVINE, Calif., August 11, 2016 - ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary healt
Read more →NAGE: ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
FOR IMMEDIATE RELEASE: ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors IRVINE, Calif., June 7, 2016 - ChromaDex Corp. (NASDAQ: CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that
Read more →NAGERESIGNATION LETTER
Chairman of the Board Chromades Corporation 10005 Muirlands Blvd. Irvine, California 92616 Effective immediately I hereby tender my resignation form all positions with ChromaDex Corporation (the "Company"), including as a member of the board of directors and as a member of th
Read more →NAGEChromaDex Approved for Listing on The NASDAQ Capital Market -Company Will Begin Trading on NASDAQ on Monday
ChromaDex Approved for Listing on The NASDAQ Capital Market -Company Will Begin Trading on NASDAQ on Monday, April 25, 2016- IRVINE, Calif., April 21, 2016 - ChromaDex Corp. (OTCQX: CDXCD) (OTCQX: CDXC), an innovator of proprietary health, wellness, and nutritional ingredients,
Read more →NAGEChromaDex Announces Reverse Stock Split as Company Seeks to List its Common Stock on The NASDAQ Capital Market IRVINE, Calif., Tuesday
ChromaDex Announces Reverse Stock Split as Company Seeks to List its Common Stock on The NASDAQ Capital Market IRVINE, Calif., Tuesday, April 12, 2016 - ChromaDex Corp. (OTCQX: CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science
Read more →NAGEINVESTOR PRESENTATION OF CHROMADEX CORPORATION ex99-1.htm
INVESTOR PRESENTATION OF CHROMADEX CORPORATION ex99-1.htm
Read more →NAGEChromaDex Enters Into an Exclusive Joint Development Agreement with The Procter & Gamble Company
ChromaDex Enters Into an Exclusive Joint Development Agreement with The Procter & Gamble Company IRVINE, Calif., November 5, 2015 ChromaDex Corp. (OTCQX: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for diet
Read more →NAGEChromaDex Announces $2,000,000 Registered Direct Offering - Financing Increases Stockholder Equity as Company Pursues an Uplisting to a National Exchange
ChromaDex Announces $2,000,000 Registered Direct Offering - Financing Increases Stockholder Equity as Company Pursues an Uplisting to a National Exchange - IRVINE, Calif., November 5, 2015 - ChromaDex Corp. (OTCQX: CDXC), an innovator of proprietary health, wellness, and nutrit
Read more →NAGEChromaDex Welcomes Business & Media Executive and Academy Award Winning Producer, Rob Fried, to Its Board of Directors IRVINE, Calif., July 13th, 2015 - ChromaDex Corp. (OTCQX: CDXC ), an innovator of proprietary health,
ChromaDex Welcomes Business & Media Executive and Academy Award Winning Producer, Rob Fried, to Its Board of Directors IRVINE, Calif., July 13th, 2015 - ChromaDex Corp. (OTCQX: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-
Read more →NAGEChromaDex Expands Patent Rights to Pterostilbene
ChromaDex Expands Patent Rights to Pterostilbene IRVINE, Calif., June 4, 2015 - ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and phar
Read more →NAGEChromaDex Announces Exclusive Worldwide License and Supply Agreement for Anthocyanin Rich Suntava Purple Corn - ChromaDex Will Use Proprietary Suntava Purple Corn to Produce a Highly Concentrated Anthocyanin Ingredient a
ChromaDex Announces Exclusive Worldwide License and Supply Agreement for Anthocyanin Rich Suntava Purple Corn - ChromaDex Will Use Proprietary Suntava Purple Corn to Produce a Highly Concentrated Anthocyanin Ingredient at a Price Point that Should Appeal to Mass Markets - Irvi
Read more →NAGEChromaDex Appoints Former GlaxoSmithKline Executive, Jeff Baxter, to Its Board of Directors
ChromaDex Appoints Former GlaxoSmithKline Executive, Jeff Baxter, to Its Board of Directors IRVINE, Calif., April 20, 2015 - ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary sup
Read more →NAGEChromaDex Appoints Former Nestl Executive, Steve Allen, as Chairman - Company Reduces Number of Directors from Nine to Seven
ChromaDex Appoints Former Nestl Executive, Steve Allen, as Chairman - Company Reduces Number of Directors from Nine to Seven - IRVINE, Calif., March 3, 2015 - ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and scienc
Read more →NAGEChromaDex's NIAGEN Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study - Results Confirm That NR Increases the Mitochondrial Co-enzyme NAD+ and is Safe - - Full Study Results to be Peer Reviewed fo
ChromaDex's NIAGEN Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study - Results Confirm That NR Increases the Mitochondrial Co-enzyme NAD+ and is Safe - - Full Study Results to be Peer Reviewed for Scientific Publication - IRVINE, Calif., Feb. 11, 2015
Read more →NAGEChromaDex Receives $750,000 Cash from Previous Sale of its BluScience Line
ChromaDex Receives $750,000 Cash from Previous Sale of its BluScience Line IRVINE, Calif., Dec. 3, 2014 - ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and b
Read more →NAGEChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support
ChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support IRVINE, Calif. - December 2, 2014 - ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredie
Read more →NAGEChromaDex Secures $5.0 Million in Growth Capital Financing from Hercules
ChromaDex Secures $5.0 Million in Growth Capital Financing from Hercules IRVINE, Calif. - September 30, 2014 - ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food
Read more →NAGEUniversity of California Irvine Completes Pterostilbene Study For Prevention of Skin Damage from UV Exposure - ChromaDex Licensed Exclusive Rights to Several Patent Applications for Use of Pterostilbene in Topical Skin C
University of California Irvine Completes Pterostilbene Study For Prevention of Skin Damage from UV Exposure -ChromaDex Licensed Exclusive Rights to Several Patent Applications for Use of Pterostilbene in Topical Skin Care Applications - IRVINE, Calif. - September 22, 2014 - C
Read more →NAGEChromaDex Licenses Exclusive Patent Rights from Dartmouth College for Pharmaceutical Use of Nicotinamide Riboside (NR)
ChromaDex Licenses Exclusive Patent Rights from Dartmouth College for Pharmaceutical Use of Nicotinamide Riboside (NR) IRVINE, Calif. - June 3, 2014 - ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based s
Read more →NAGEChromaDex Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX - Four Year Deal is for ChromaDex's NIAGEN Nicotinamide Riboside and PURENERGY
ChromaDex Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX - Four Year Deal is for ChromaDex's NIAGEN Nicotinamide Riboside and PURENERGY - IRVINE, Calif. - January 6, 2014 - ChromaDex Corporation (OTCBB: CDXC), an innovative natural products comp
Read more →NAGE1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30
1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30-
Read more →NAGEChromaDex Acquires New Exclusive Worldwide Patent Rights for pTeroPure Pterostilbene Relating to Skin Care - Company also Acquires Right of First Refusal for Combined Use of Pterostilbene and Quercetin for the Prevention
ChromaDex Acquires New Exclusive Worldwide Patent Rights for pTeroPure Pterostilbene Relating to Skin Care - Company also Acquires Right of First Refusal for Combined Use of Pterostilbene and Quercetin for the Prevention and/or Treatment of Skin Cancer - IRVINE, Calif. - Augu
Read more →NAGENIAGEN SUPPLY AGGREEMENT THIS AGREEMENT (the "Agreement"), is made and entered into as of
NIAGEN SUPPLY AGGREEMENT THIS AGREEMENT (the "Agreement"), is made and entered into as of July 9, 2013 (the "Effective Date") by and between Thorne Research, Inc., with offices at 25820 Highway 2 West, Sandpoint, Idaho 83864 ("Buyer") and ChromaDex, Inc., with offices at 10005 M
Read more →NAGEhtm ChromaDex Adds to Its Exclusive Worldwide Patent Rights for Nicotinamide Riboside (NR) with Washington University Agreement - NR is a Newly Discovered Vitamin and is a Natural Metabolite of Niacin
ChromaDex Adds to Its Exclusive Worldwide Patent Rights for Nicotinamide Riboside (NR) with Washington University Agreement - NR is a Newly Discovered Vitamin and is a Natural Metabolite of Niacin (Vitamin B3) - - Found in Milk, NR is Linked to Numerous Health Benefits - IRVI
Read more →NAGE1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24
1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24-
Read more →NAGEChromaDex Acquires Spherix Consulting - Spherix Consulting Brings Technical and Regulatory Services to Further Build ChromaDex's Offering of Science-Based Solutions
ChromaDex Acquires Spherix Consulting - Spherix Consulting Brings Technical and Regulatory Services to Further Build ChromaDex's Offering of Science-Based Solutions - IRVINE, Calif. - December 3, 2012 - ChromaDex Corporation (OTCQB: CDXC) ("ChromaDex") an innovative natural pr
Read more →NAGEPresentation Abstract Session: 13-Poster Session II Thursday
Presentation Abstract Session: 13-Poster Session II Thursday, Sep 20, 2012, 1:45 PM - 3:30 PM Presentation: 617 - Impact of Pterostilbene On Blood Pressure and Other Metabolic Parameters In Adults Location: Regency Pres. Time: Thursday, Sep 20, 2012, 1:45 PM - 3:30 PM Cat
Read more →NAGE1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23
1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23-
Read more →NAGEChromaDex Licenses Exclusive Patent Rights for Nicotinamide Riboside (NR) Vitamin Technologies from Dartmouth College NR, a Newly Discovered and Unique Composition of Niacin (Vitamin B3) Found in Milk, is Linked to Multi
ChromaDex Licenses Exclusive Patent Rights for Nicotinamide Riboside (NR) Vitamin Technologies from Dartmouth College NR, a Newly Discovered and Unique Composition of Niacin (Vitamin B3) Found in Milk, is Linked to Multiple Health Benefits Including Resistance to Weight Gain, Im
Read more →NAGEChromaDex Corp. Names Co-founder Frank Jaksch CEO & President
ChromaDex Corp. Names Co-founder Frank Jaksch CEO & President IRVINE, Calif., June 12, 2012 /PRNewswire/ -- ChromaDex Corporation (OTC BB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement,
Read more →NAGEChromaDex Announces Management Changes
ChromaDex Announces Management Changes IRVINE, Calif. - February 17, 2012 -ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and phar
Read more →NAGEChromaDex to Raise $10.85M in Sale of Common Stock
ChromaDex to Raise $10.85M in Sale of Common Stock IRVINE, Calif., Feb. 1, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & bevera
Read more →NAGEINVESTOR PRESENTATION ex99-1.htm
INVESTOR PRESENTATION ex99-1.htm
Read more →NAGEIRVINE, Calif.
IRVINE, Calif., Jan. 23, 2012 -- /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries and m
Read more →NAGEINVESTOR PRESENTATION SLIDES ex99-1.htm EX 99.1 http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-investorKit http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-investorKit
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-investorKit http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-investorKit
Read more →NAGEChromaDex Receives Investment from The Frost Group, LLC - Capital Will Allow ChromaDex to Pursue Clinical Studies & Commercialization of its New pTeroPure Pterostilbene - IRVINE, CALIFORNIA (
ChromaDex Receives Investment from The Frost Group, LLC - Capital Will Allow ChromaDex to Pursue Clinical Studies & Commercialization of its New pTeroPure Pterostilbene - IRVINE, CALIFORNIA (April 26, 2010) ChromaDex Corporation (OTCBB: CDXC), a natural products chemistry comp
Read more →Competitive Position
How NAGE ranks across every disease it competes inCompetitive Position is a premium feature
See how NAGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial